 |
|
Treatment of Systemic Fungal Infections With Liposomal Amphotericin B
Gabriel Lopez-Berestein, MD;
Gerald P. Bodey, MD;
Victor Fainstein, MD;
Michael Keating, MD;
Lawrence S. Frankel, MD;
Barry Zeluff, MD;
Layne Gentry, MD;
Kapil Mehta, PhD
Arch Intern Med. 1989;149(11):2533-2536.
Abstract
• Forty-six patients with systemic fungal infections were treated with liposomal amphotericin B. Twenty-one patients had disseminated candidiasis, 19 had aspergillosis, and the rest had a variety of other fungal infections. Forty patients failed to respond to conventional amphotericin B therapy, and 6 patients were given liposomal amphotericin B because conventional amphotericin B caused severe side effects. Twenty-four patients had a complete response, and 22 patients failed to respond. No short- or long-term toxic reactions were observed. The acute side effects such as fever, chills, and potassium loss were infrequent and milder than those commonly observed with conventional amphotericin B. No chronic renal, hematologic, or central nervous system side effects were observed. Liposomal amphotericin B therapy was effective and less toxic than conventional amphotericin B therapy.
(Arch Intern Med. 1989;149:2533-2536)
Author Affiliations
From the Section of Immunobiology and Drug Carriers, Division of Medicine (Drs Lopez-Berestein and Mehta), the Departments of Hematology (Dr Keating) and Pediatrics (Dr Frankel), and the Section of Infectious Diseases, Division of Medicine, Department of Internal Medicine (Drs Bodey and Fainstein), The University of Texas M. D. Anderson Cancer Center, and the Department of Infectious Diseases, St Luke's Hospital (Drs Zeluff and Gentry), Houston, Tex.
Footnotes
Accepted for publication June 7,1989.
Reprint requests to Immunobiology and Drug Carriers Section, Division of Medicine, Box 41, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (Dr Lopez-Berestein).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis
Ortoneda et al.
Antimicrob. Agents Chemother. 2002;46:2273-2275.
ABSTRACT
| FULL TEXT
Persistent cavitations in pulmonary mucormycosis after apparently successful amphotericin B
Donado-Una et al.
Eur. J. Cardiothorac. Surg. 2002;21:940-942.
ABSTRACT
| FULL TEXT
Current and future antifungal therapy: new targets for antifungal agents
Andriole
J Antimicrob Chemother 1999;44:151-162.
ABSTRACT
| FULL TEXT
Human mycoses: drugs and targets for emerging pathogens
Georgopapadakou and Walsh
Science 1994;264:371-373.
Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia
Pizzo
NEJM 1993;328:1323-1332.
FULL TEXT
Cardiopulmonary Toxicity after Liposomal Amphotericin B Infusion
Levine et al.
ANN INTERN MED 1991;114:664-666.
ABSTRACT
Sepsis
Wakeford and Hardin
Journal of Pharmacy Practice 1991;4:269-280.
Nosocomial Amphotericin B: Current Status
SAROSI
Arch Intern Med 1989;149:2402-2403.
ABSTRACT
|
